N-Formyl-Met-Leu-Phe (fMLP) is a chemotactic peptide and a specific ligand of N-formyl peptide receptor (FPR), which can inhibit TNF-alpha secretion. N-Formyl-Met-Leu-Phe (fMLF) acts as an agonist at formyl peptide receptors (FPR; Ki = 0.8 pM). N-Formyl-Met-Leu-Phe promotes osteoblastic commitment and suppresses adipogenic commitment under osteoblastic differentiation conditions. N-Formyl-Met-Leu-Phe stimulates osteogenesis is associated with increased expression of osteogenic markers and mineralization. N-Formyl-Met-Leu-Phe inhibits expression of peroxisome proliferator-activated receptor-γ1. N-Formyl-Met-Leu-Phe promotes bone formation in zebrafish and rabbits. Treatment with N-Formyl-Met-Leu-Phe results in increased expression of Runx2. Bone marrow spaces are widely formed, and connective tissue covering bone is dense, like periosteum, in N-Formyl-Met-Leu-Phe-treated calvaria.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||DMSO ≥ 60 mg/mL|
 Min Kyoung Shin, et al. J Biol Chem. N-formyl-methionyl-leucyl-phenylalanine (fMLP) promotes osteoblast differentiation via the N-formyl peptide receptor 1-mediated signaling pathway in human mesenchymal stem cells from bone marrow
|Related TNF-alpha Products|
UTL-5g is a novel potential chemoprotective agent, TNF-α inhibitor that reduces cisplatin-induced side effects including nephrotoxicity, hepatotoxicity and hematotoxicity.
Benpyrine racemate ((Rac)-Benpyrine) is a racemate of Benpyrine, Benpyrine racemate ((Rac)-Benpyrine) is a potent and orally active TNF-α inhibitor and has the potential for TNF-α mediated inflammatory and autoimmune disease research.
Cynaropicrin is a sesquiterpene lactone which can inhibit tumor necrosis factor (TNF-α) release and the increase of cartilage degradation factor (MMP13) and suppresses NF-κB signaling.
Roquinimex (LS2616; FCF89) is a quinoline-3-carboxamide with potential antineoplastic activity, which increases NK cell activity and macrophage cytotoxicity.
Etanercept is a dimeric fusion protein consisting of two ligand-binding domains of human p75 tumor necrosis factor receptor and the human IgG1 Fc portion.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.